Oneness Biotech announced yesterday (15th) that it has reached a licensing agreement with Denmark’s LEO Pharma with regard to the new antibody drug technology FB825 which was developed by Oneness and licensed amounted US$530 million (approximately NT$16 billion). Oneness mentioned that phase II a (2a) clinical trial for atopic dermatitis will be implemented in the U.S. and expected to be completed within the first half of next year. FB825 has been approved by the U.S. FDA for three Phase II clinical trials, including atopic dermatitis, allergic asthma, and Hyger immune globulin E syndrome, and has obtained the orphan drug qualification approved for the treatment of  hyper immune globulin E syndrome.